{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011430","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.176377+00:00","generated_at":"2026-06-25T02:50:35.812635+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cyclerion (CYCN) reports positive topline data for CY6463 in MELAS study; improvements in biomarkers","bullets":["Open-label, eight-patient study showed improvements in lactate, GDF-15, inflammatory biomarkers, cerebral blood flow, and functional connectivity after 29 days.","CY6463 was well tolerated with no serious adverse events or treatment discontinuations; PK consistent with Phase 1.","75% of patients were on standard-of-care arginine or citrulline; effects more pronounced in patients with greater baseline disease burden.","Data support further development of CY6463 in CNS diseases with mitochondrial dysfunction, including schizophrenia and Alzheimer's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011430","json":"https://secwatch.observer/filing/0000950170-22-011430.json","markdown":"https://secwatch.observer/filing/0000950170-22-011430.md","text":"https://secwatch.observer/filing/0000950170-22-011430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022011430/0000950170-22-011430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022011430/cycn-20220610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:50:35.812635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}